Lilly (Eli) vs Modal

Side-by-side comparison of AI visibility scores, market position, and capabilities

Lilly (Eli) leads in AI visibility (88 vs 45)
Lilly (Eli) logo

Lilly (Eli)

LeaderHealthcare Tech

Enterprise

Indianapolis pharma leader (NYSE: LLY) $45.1B FY2024 revenue (+32%); Mounjaro $11.4B + Zepbound $4.9B tirzepatide GLP-1, oral orforglipron Phase 3, $18B manufacturing expansion competing with Novo Nordisk.

AI VisibilityBeta
Overall Score
A88
Category Rank
#125 of 290
AI Consensus
51%
Trend
stable
Per Platform
ChatGPT
89
Perplexity
79
Gemini
99

About

Eli Lilly and Company is an Indianapolis, Indiana-based global pharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: LLY) as an S&P 500 Health Care component — discovering, developing, and commercializing medicines across diabetes, obesity, oncology, immunology, and neuroscience through approximately 43,000 employees worldwide. In fiscal year 2024, Eli Lilly reported revenues of $45.1 billion (+32% year-over-year) — driven by the historic commercial launch of Mounjaro (tirzepatide for type 2 diabetes, $11.4B revenue) and Zepbound (tirzepatide for obesity and obstructive sleep apnea, $4.9B revenue) — making Eli Lilly one of the fastest-growing large pharmaceutical companies in history and elevating its market capitalization above $700 billion at peak 2024 valuation, briefly making Lilly the most valuable healthcare company globally. CEO Dave Ricks' strategic investment in tirzepatide manufacturing capacity — committing $18+ billion to new US manufacturing sites in Indiana, Wisconsin, and North Carolina — reflects Lilly's execution of unprecedented pharmaceutical demand that has consistently outpaced supply since Mounjaro's 2022 approval and Zepbound's 2023 FDA approval for obesity. The GLP-1/GIP dual agonist mechanism (tirzepatide activates both GLP-1 and GIP incretin receptors, versus semaglutide's single GLP-1 activation) produces superior efficacy results — SURMOUNT-1 trial showing 22.5% average body weight loss with tirzepatide versus 15% with semaglutide (Ozempic/Wegovy) — establishing tirzepatide as the most effective approved obesity pharmacotherapy.

Full profile
Modal logo

Modal

EmergingAI & Machine Learning

Serverless ML

Serverless GPU cloud platform for AI/ML with Python-native deployment and per-second billing; developer-favorite scaling from zero competing with Replicate and Beam for AI compute.

AI VisibilityBeta
Overall Score
C45
Category Rank
#1 of 1
AI Consensus
55%
Trend
up
Per Platform
ChatGPT
38
Perplexity
50
Gemini
53

About

Modal is a serverless cloud computing platform purpose-built for AI and machine learning workloads — providing on-demand GPU compute that scales instantly from zero with per-second billing, container management, distributed training support, and a Python-native developer experience that makes running ML workloads in the cloud feel as simple as running code locally. Founded in 2021 in New York City and backed by Redpoint Ventures and other investors, Modal has grown rapidly as AI development has accelerated demand for flexible, developer-friendly GPU infrastructure.\n\nModal's developer experience is its primary differentiator — engineers write Python functions decorated with @modal.function() and deploy them to the cloud with a single command, with Modal handling container building, GPU provisioning, auto-scaling, and execution. The platform supports training jobs that need distributed compute across multiple GPUs, model serving endpoints that scale to zero when unused (eliminating idle GPU costs), and batch inference jobs that process large datasets. The per-second billing model means developers pay only for actual compute time, not provisioned instances.\n\nIn 2025, Modal competes in the AI infrastructure market with Replicate, Beam, Banana, and major cloud providers' managed ML services (AWS SageMaker, Google Vertex AI, Azure ML) for serverless GPU compute. The market for AI-specific cloud infrastructure has grown dramatically as the number of ML engineers deploying models to production has expanded — traditional cloud providers require significant DevOps expertise to use GPU instances effectively, while Modal's Python-native approach reduces the barrier to entry. Modal has attracted a strong developer following among AI researchers and ML engineers building production AI applications. The 2025 strategy focuses on growing the developer community, adding enterprise features (dedicated GPU capacity, private networking, compliance), and expanding the hardware options available (H100 GPUs, custom accelerators).

Full profile

AI Visibility Head-to-Head

88
Overall Score
45
#125
Category Rank
#1
51
AI Consensus
55
stable
Trend
up
89
ChatGPT
38
79
Perplexity
50
99
Gemini
53
90
Claude
39
80
Grok
37

Capabilities & Ecosystem

Capabilities

Only Modal
Serverless ML

Integrations

Only Lilly (Eli)

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.